Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why This Once-Promising HIV Candidate Could Be in Trouble

TheMotleyFool

0 0

Why This Once-Promising HIV Candidate Could Be in Trouble

Merck (NYSE: MRK) recently paused enrollment for late-stage clinical studies evaluating islatravir as potential pre-exposure prophylaxis for HIV. In this Motley Fool Live video recorded on Dec. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss whether this once-promising HIV candidate could be in trouble.

Source Fool.com

Like: 0

MRK

Share